Sakai Chemical Industry (4078) FY2027 Q1 Earnings Report

Quick View

Executive Summary

Although revenue increased in the quarter, operating income declined, and the increase in net income was dependent on temporary factors. Revenue was ¥21.47B (+6.6% YoY), Operating Income was ¥1.71B (-10.5%), and Ordinary Income was ¥1.88B (-2.5%). Net Income increased substantially to ¥2.04B (+56.8%), primarily due to the recognition of a ¥1.17B gain on the sale of fixed assets as extraordinary income. However, the profitability of the core business deteriorated due to a decline in the gross profit margin.

Factors Affecting Performance

【Revenue】Revenue increased 6.6% YoY to ¥21.47B. By segment, Electronic Materials maintained the largest revenue scale at ¥3.36B (+17.2%), while Catalysts (+40.1%) and Cosmetic Materials (+58.5%) posted strong growth. In contrast, Titanium Oxide and Zinc Products (-30.0%) and Organic Chemicals (-9.5%) reported lower revenue due to weakening market conditions.

【Profit and Loss】Operating Income declined 10.5% YoY to ¥1.71B. The gross profit margin declined to 25.0% from the previous year, with the effects of raw material costs and product mix offsetting the benefits of selling, general and administrative expense controls. Ordinary Income was ¥1.88B (-2.5%), as non-operating income—including ¥0.14B in dividend income and ¥0.05B in foreign exchange gains—partially offset the decline in Operating Income. Net Income was ¥2.04B (+56.8%), but the ¥1.17B gain on the sale of fixed assets recognized as extraordinary income was the primary contributor. The earnings profile was therefore characterized by higher revenue but lower core operating income, alongside higher net income driven by temporary factors.

Segment Analysis

Electronic Materials was the largest contributor to consolidated profit, with revenue of ¥3.36B (15.7% of total revenue, +17.2% YoY) and Operating Income of ¥0.58B (+22.1%), representing a profit margin of 17.3%. Barium also maintained its position as a highly profitable segment, with revenue of ¥1.72B (+7.4%) and a profit margin of 17.6%. Cosmetic Materials increased revenue to ¥0.53B (+58.5%), but its operating loss widened to ¥0.11B, including an impairment loss on fixed assets of ¥0.12B. The Medical Business also recorded an operating loss of ¥0.02B, compared with a profit of ¥0.006B in the previous year, despite revenue of ¥2.11B (+0.5%). Titanium Oxide and Zinc Products were significantly affected by deteriorating market conditions, with revenue of ¥1.94B (-30.0%) and profit of ¥0.14B (-65.3%). Differences in profitability among segments are diluting the Company-wide margin.

Key Financial Indicators

【Profitability】The Operating Income margin declined to 7.9% from 9.5% in the previous year (¥1.90B/¥20.14B), while the gross profit margin also deteriorated to 25.0%, indicating weakness in the profitability of the core business. The Net Income margin improved to 9.5% from 6.4% in the previous year, but this was substantially boosted by extraordinary income.【Earnings Quality】The net amount of ¥1.03B resulting from extraordinary income of ¥1.17B and extraordinary losses of ¥0.14B contributed to the increase in Profit Before Tax of ¥2.91B. The gap between Ordinary Income of ¥1.88B and Net Income of ¥2.04B was therefore largely attributable to temporary factors.【Investment Efficiency】ROE was 2.4%, while the Equity Ratio was 69.9%, indicating a structure that prioritizes financial stability over efficient use of capital.【Financial Soundness】The Equity Ratio rose to 69.9% from 67.3% in the previous year. Cash and deposits increased to ¥17.72B (+14.3% YoY), while long-term borrowings declined to ¥4.05B (-12.7% YoY), further stabilizing the financial base.

Cash Flow Analysis

Although detailed disclosure of the cash flow statement is not available, the movement of funds can be assessed based on changes in the balance sheet. Cash and deposits amounted to ¥17.72B, an increase of ¥2.22B from the previous year. Inventories declined by ¥1.02B YoY to ¥14.22B, indicating progress in inventory reduction, while accounts payable increased by ¥1.56B to ¥10.20B, suggesting that the use of payment terms supported short-term liquidity. Recognition of the ¥1.17B gain on the sale of fixed assets is believed to have been accompanied by cash inflows from asset sales and may have contributed to the increase in cash balances. Long-term borrowings declined by ¥0.59B YoY to ¥4.05B, indicating progress in reducing interest-bearing debt. Net assets increased by ¥4.77B YoY to ¥83.69B, as the accumulation of retained earnings and other comprehensive income strengthened the financial base.

Earnings Quality

Attention should be paid to the high degree of dependence of the current-period earnings structure on temporary factors. Recurring earnings are represented by Operating Income of ¥1.71B and Ordinary Income of ¥1.88B, which reflects non-operating income of ¥0.24B and non-operating expenses of ¥0.06B. Ordinary Income therefore declined only modestly, by -2.5% from the previous year. In contrast, Profit Before Tax, after reflecting extraordinary income of ¥1.17B from the gain on the sale of fixed assets and extraordinary losses of ¥0.14B, including an impairment loss of ¥0.12B, amounted to ¥2.91B. The ¥1.03B difference from Ordinary Income consisted of non-recurring items. More than half of Net Income of ¥2.04B was therefore attributable to net extraordinary gains and losses, indicating that the increase in final profit was driven by a temporary asset-sale effect rather than an improvement in sustainable earnings power. Comprehensive Income was ¥3.05B, exceeding Net Income of ¥2.04B. The primary reason was a ¥0.96B increase in valuation differences on securities, indicating that changes in the value of non-operating assets supported Comprehensive Income.

Earnings Forecast and Guidance

Progress against the full-year forecast was 26.3% for Revenue (¥21.47B/¥81.70B), 28.4% for Operating Income (¥1.71B/¥6.00B), and 30.8% for Ordinary Income (¥1.88B/¥6.10B). Operating Income and Ordinary Income are progressing slightly ahead of the simple progress benchmark of 25%. However, the full-year Operating Income forecast assumes a -7.0% YoY decline, and the -10.5% decline in Q1 is broadly in line with this plan. No revisions were made to the earnings or dividend forecasts, and management has maintained its full-year plan.

Shareholder Returns

The Company’s dividend forecast is DPS of ¥160, implying a Payout Ratio of approximately 55.7% based on forecast EPS of ¥287.37. The Company plans to increase the full-year dividend from the previous year’s DPS of ¥65 (interim actual), and no revision has been made to the dividend forecast. Given the financial base consisting of an Equity Ratio of 69.9% and cash and deposits of ¥17.72B, there are no apparent concerns regarding dividend sustainability based on the information available as of the current quarter.

Risk Factors

1. Deterioration in market conditions for commodity-oriented segments: Titanium Oxide and Zinc Products recorded revenue of -30.0% and profit of -65.3%, while Organic Chemicals recorded revenue of -9.5% and profit of -44.2%. Both were significantly affected by weakening market conditions and contributed to an estimated decline of -240bp in the Company-wide gross profit margin.

2. Deterioration in the profitability of Cosmetic Materials and the Medical Business: Cosmetic Materials recorded an operating loss of ¥0.11B, worsening from a loss of ¥0.065B in the previous year, and recognized an impairment loss of ¥0.12B. The Medical Business also fell into an operating loss of ¥0.02B from the previous year. Both segments are diluting the Company-wide margin.

3. Dependence of Net Income on temporary factors: The ¥1.17B extraordinary gain from the sale of fixed assets made a substantial contribution to Net Income of ¥2.04B. The level of profit in subsequent periods after this factor has dissipated therefore requires close monitoring.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

The Operating Income margin is slightly below the industry median, while the Net Income margin exceeds the industry median due to the boost from extraordinary income.

Growth and Capital Efficiency

The Revenue growth rate is slightly above the industry median and is positioned around the middle of the range.

※Source: Compiled by the Company

Key Takeaways from the Results

1. The Operating Income margin declined to 7.9% from 9.5% in the previous year, with deterioration in the gross profit margin affecting core earnings power. Trends in the market-sensitive segments—Titanium Oxide and Zinc Products and Organic Chemicals—will be key to recovering the gross profit margin.

2. The 56.8% increase in Net Income depended on the non-recurring ¥1.17B gain on the sale of fixed assets. On an Ordinary Income basis, profit declined -2.5%; monitoring trends in Ordinary Income and Operating Income is therefore useful for assessing sustainable earnings trends.

3. The Electronic Materials segment continued to achieve double-digit growth in both revenue and profit, with a profit margin of 17.3%, exceeding the Company-wide average. Whether the segment’s revenue contribution continues to expand will be a key point in assessing changes in the Company-wide earnings structure.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade period). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥4,338–¥4,584 at ±1% for the cost of equity, and ¥4,444–¥4,468 at ±0.1 for ω.

Notes:

• Because progress of Net Income against the full-year forecast (45%) exceeds the standard benchmark (25%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies progressing ahead of plan tend to exceed their forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).

(Model used: Residual Income Model / Interest Rate Reference Month: 2026-07 / This value does not forecast or guarantee future share prices)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a mixed quarter: sales growth remained positive and reported net profit rose sharply, but core operating profitability weakened and the bottom-line result was dominated by asset-sale gains. Revenue increased 6.6% year on year to JPY21.47bn. Operating income fell 10.5% to JPY1.71bn despite the higher sales base. Ordinary income was comparatively resilient, declining only 2.5% to JPY1.88bn, aided by non-operating income of JPY0.24bn. Gross profit declined 2.8% to JPY5.36bn as cost of sales increased 10.7%, faster than revenue growth. Consequently, gross margin compressed by approximately 240bp year on year to 25.0% from 27.4%. Operating margin compressed by approximately 160bp to 7.9% from 9.5%. SG&A increased only 1.3% to JPY3.66bn, materially below revenue growth, indicating that the operating-income decline principally reflected gross-margin pressure rather than overhead inflation. Profit attributable to owners rose 56.0% to JPY2.00bn, and EPS increased to JPY130.66 from JPY79.66. However, JPY1.17bn of gain on sale of fixed assets lifted profit before tax to JPY2.91bn, while extraordinary losses included JPY0.12bn of impairment and JPY0.02bn of fixed-asset disposal losses. The gain on asset sales alone equaled 58.6% of profit attributable to owners, and the reported quality alert measures one-time items at 65.3% of net income. Hence, reported net margin of 9.3% substantially overstates the recurring earnings profile implied by the 7.9% EBIT margin. Comprehensive income rose to JPY3.05bn from JPY0.80bn, supported by JPY1.02bn of OCI, principally an improvement in securities valuation. The balance sheet remains conservatively capitalized, with a 250.9% current ratio, 0.43x debt-to-equity ratio, and 47.36x interest coverage. Nevertheless, working-capital intensity is a material operating issue, reflected in quality alerts for 89-day annualized DSO, 131-day annualized DIO, an additional 81-day inventory-days alert, and a 162-day annualized cash conversion cycle. Management retained full-year guidance, which implies Q1 progress above the seasonal 25% benchmark for sales and operating profit and particularly elevated progress for attributable profit because of the non-recurring asset-sale gain. The principal issue for subsequent quarters is whether electronic materials and other growth businesses can sustain sales momentum while restoring gross margin and releasing cash tied up in receivables and inventory.

Profitability Analysis

Annualized DuPont ROE is 9.6%, comprising a 9.3% net profit margin, 0.717x asset turnover, and 1.43x financial leverage. The largest driver of the reported ROE outcome is the elevated Q1 net margin, but this is not a clean indicator of recurring profitability because extraordinary gain on sale of fixed assets was JPY1.17bn. The core operating measure is weaker: EBIT margin was 7.9%, below the 8-15% benchmark range characterized as good and down about 160bp year on year. Gross-margin compression of about 240bp was the fundamental earnings headwind, as cost of sales grew 10.7% versus 6.6% revenue growth. SG&A discipline was favorable, with expenses up only 1.3%, and therefore SG&A did not cause the operating-margin contraction. The five-factor analysis shows a 0.688 tax burden, equivalent to a 30.0% effective tax rate, which is broadly normal for a Japanese corporate taxpayer. The 1.706x interest burden is above 1.0x because profit before tax included the extraordinary asset-sale gain; it should not be interpreted as a recurring financing benefit. Interest expense was only JPY0.04bn and interest coverage was a very strong 47.36x, confirming that debt service is not constraining profitability. Dividend income of JPY0.14bn and FX gains of JPY0.05bn modestly supported ordinary income. Profitability sustainability therefore depends less on leverage and more on recovery in product mix, selling prices, input-cost pass-through, and utilization across the manufacturing portfolio.

Growth Assessment

Q1 revenue growth of 6.6% exceeded the full-year forecast growth assumption of 0.3%, with JPY21.47bn representing 26.3% of the JPY81.70bn full-year sales target. Operating-income progress was 28.4% of full-year guidance, above the standard Q1 pace of 25%, even though Q1 operating income declined 10.5% year on year. Ordinary-income progress was 30.8% of the JPY6.10bn forecast, also ahead of the standard pace. Profit attributable to owners reached 45.5% of the JPY4.40bn forecast, but this apparent outperformance is not representative of recurring run-rate because the JPY1.17bn asset-sale gain drove a significant share of Q1 earnings. The full-year forecast calls for operating income to decline 7.0% year on year and ordinary income to decline 6.8%, indicating that management is not assuming a broad-based near-term margin recovery. Electronic materials was the largest operating-profit contributor and is the core business this quarter, generating JPY3.36bn of external sales, up 17.2% year on year, and JPY0.58bn of segment profit, up 22.1%; its segment margin improved to 17.3% from 16.6%. Other was the second-largest reported profit contributor, with sales of JPY3.21bn, up 38.8%, and segment profit of JPY0.45bn, up 42.7%, for a 14.0% margin. Organic chemicals sales declined 9.4% to JPY1.92bn and segment profit fell 44.2% to JPY0.26bn, reducing margin to 13.3% from 21.6%. Titanium dioxide and zinc products experienced the sharpest deterioration among larger businesses: sales declined 30.6% to JPY1.87bn and segment profit fell 65.3% to JPY0.14bn, with margin falling to 7.6% from 15.2%. Resin additives maintained sales growth of 3.4% to JPY3.11bn, but segment profit fell 5.6% to JPY0.32bn. Cosmetics materials sales rose 58.5% to JPY0.53bn but recorded a JPY0.11bn segment loss, versus a JPY0.06bn loss a year earlier; the segment also recorded JPY0.12bn of impairment. Medical business sales were broadly stable at JPY2.11bn, but it shifted to a JPY0.02bn segment loss from a JPY0.01bn profit. Segment profit before unallocated corporate costs declined 3.6% to JPY2.39bn, while unallocated corporate costs increased 19.0% to JPY0.68bn, further limiting consolidated operating-profit conversion. The mix of strong electronic-materials growth and weakness in titanium dioxide/zinc, organic chemicals, cosmetics materials, and medical business creates an uneven growth profile.

Financial Health

Liquidity is strong. Current assets of JPY67.23bn cover current liabilities of JPY26.80bn by 2.51x, well above the 1.0x warning threshold. The quick ratio is also robust at 1.98x, and working capital totals JPY40.43bn. Cash and deposits of JPY17.72bn exceed short-term loans of JPY8.47bn by 2.09x, providing direct liquidity coverage for near-term borrowings. Although 67.7% of interest-bearing debt is short term, triggering the refinancing-risk quality alert, the maturity profile is mitigated by the substantial cash balance, strong current ratio, and low aggregate leverage. Interest-bearing debt totals JPY12.52bn, equivalent to 0.43x owners' equity, while debt/capital is only 13.0%; both indicate conservative balance-sheet leverage and no D/E-related warning. Total liabilities declined 5.7% year on year to JPY36.12bn, while total equity increased 6.0% to JPY83.69bn. Long-term loans declined 12.8% year on year to JPY4.05bn, whereas short-term loans increased modestly by 1.4% to JPY8.47bn. The JPY3.62bn net defined-benefit liability is a relevant long-term obligation, though it is manageable relative to the JPY82.44bn owners' equity base. Goodwill is only JPY0.64bn, or 0.8% of equity and 0.5% of assets, so balance-sheet exposure to acquisition-value retention is immaterial. PPE of JPY42.57bn represents 35.5% of total assets, consistent with a capital-intensive chemical and materials manufacturing model. Investment securities increased to JPY7.62bn and valuation gains contributed to OCI, which supports equity but remains exposed to market-price movements.

Notable B/S Changes

Investment securities: +JPY1.40bn (+22.6%) year on year to JPY7.62bn - higher marketable-investment exposure and positive securities valuation OCI supported equity, but increase sensitivity to market-price movements. Long-term loans: -JPY0.59bn (-12.8%) year on year to JPY4.05bn - supports lower long-term leverage, although the debt structure remains weighted toward short-term loans. Total liabilities: -JPY2.18bn (-5.7%) year on year to JPY36.12bn - balance-sheet deleveraging contributed to the increase in the equity ratio. Total equity: +JPY4.77bn (+6.0%) year on year to JPY83.69bn - strengthened capitalization, supported by earnings and positive OCI. Net defined-benefit liability: -JPY0.50bn (-12.2%) year on year to JPY3.62bn - reduced long-term employee-benefit obligation. Finished goods: -JPY1.02bn (-6.7%) year on year to JPY14.22bn - balance declined, but inventory remains elevated relative to the annualized operating run rate indicated by the inventory-days alerts.

Cash Flow Quality

Reported earnings quality is weak because a major portion of Q1 profit arose from non-recurring asset disposals rather than operating cash generation. Gain on sale of fixed assets was JPY1.17bn, partly offset by JPY0.14bn of extraordinary losses, including JPY0.12bn of impairment in cosmetics materials. This produced a JPY1.03bn net extraordinary gain before tax and explains why profit before tax of JPY2.91bn greatly exceeded ordinary income of JPY1.88bn. The quality alert of one-time items equal to 65.3% of net income confirms that the 56.0% year-on-year increase in attributable profit should not be extrapolated. Working-capital efficiency is a significant cash-conversion risk. Annualized DSO of 89 days is above both the 60-day alert threshold and the 45-day manufacturing efficiency benchmark, indicating slow collection and substantial capital tied up in customer balances. Annualized DIO of 131 days is above the 90-day warning threshold; the additional 81-day inventory-days alert likewise remains above the 60-day manufacturing benchmark. The 162-day annualized cash conversion cycle is substantially above the 120-day warning threshold, amplifying exposure to demand volatility, inventory valuation risk, and collection delays. Accounts receivable were JPY20.99bn and electronically recorded monetary claims were JPY4.47bn, representing a sizeable proportion of the quarterly sales base. Inventories were JPY14.22bn, while raw materials and work in process were JPY5.39bn and JPY3.47bn, respectively, underscoring the operational importance of inventory planning and production scheduling. Finished-goods inventory decreased 6.7% year on year to JPY14.22bn, but the elevated inventory-days alerts indicate that inventory remains high relative to the annualized cost and sales run rate. In a chemical manufacturer, prolonged inventory holding also raises risks from commodity-price movements, product obsolescence, and demand changes. The cash-flow focus for investors should be the conversion of the revenue recovery into lower DSO, lower inventory days, and a materially shorter cash conversion cycle.

Dividend Sustainability

The unchanged full-year dividend forecast is JPY160 per share. Against forecast EPS of JPY287.37, the implied dividend payout ratio is 55.7%, within the stated sub-60% sustainability benchmark. Q1 EPS of JPY130.66 represents 45.5% of the full-year EPS forecast, but this rate is inflated by the non-recurring JPY1.17bn gain on sale of fixed assets. Accordingly, dividend capacity should be assessed primarily against the full-year recurring operating-profit outlook rather than Q1 reported earnings. The conservative balance sheet, including 13.0% debt/capital, 0.43x debt-to-equity, and JPY17.72bn of cash and deposits, supports financial flexibility for the planned dividend. However, the 162-day annualized cash conversion cycle and high receivable and inventory days are constraints on cash available for distributions because operating capital is tied up in the business. The payout outlook appears reasonable relative to forecast earnings, but its durability depends on achieving the JPY6.00bn full-year operating-income plan without relying on further disposal gains.

Risk Assessment

Business risks include Margin risk is high: cost of sales rose 10.7% while revenue rose 6.6%, compressing gross margin by about 240bp and operating margin by about 160bp. Chemical, pigment, zinc, and organic-material operations remain exposed to raw-material, energy, logistics, and selling-price pass-through volatility., Portfolio performance is uneven. Titanium dioxide and zinc products saw sales decline 30.6% and segment profit decline 65.3%, while organic chemicals profit fell 44.2%; a sustained weakness in these businesses could outweigh growth in electronic materials., Electronics-materials demand is a key positive but also a concentration risk because it was the largest segment-profit contributor at JPY0.58bn. Semiconductor and electronics end-market cyclicality, customer inventory corrections, technology shifts, and qualification requirements could affect growth., Cosmetics materials and medical business were loss-making at the segment level, and cosmetics materials incurred JPY0.12bn of impairment. Further underperformance could require additional restructuring, impairment, or portfolio actions., The 89-day annualized DSO, 131-day annualized DIO, additional 81-day inventory-days alert, and 162-day annualized cash conversion cycle indicate elevated working-capital risk. Slow collections and inventory accumulation can pressure liquidity and increase write-down risk if customer demand weakens., Chemical manufacturing carries industry-specific environmental, safety, regulatory, and product-quality risks, including tighter chemical-substance regulation, emissions requirements, plant incidents, and remediation costs..

Financial risks include The 67.7% short-term debt ratio is above the 40% alert threshold, creating a refinancing-risk flag. The immediate risk is moderated by cash/short-term debt of 2.09x, current ratio of 250.9%, and low 0.43x debt-to-equity., Reported net income is not fully recurring: one-time items are flagged at 65.3% of net income, with JPY1.17bn of asset-sale gains. This makes period-on-period earnings comparisons and valuation based on Q1 EPS less reliable., Investment securities of JPY7.62bn and JPY0.96bn of positive securities valuation OCI introduce market-value sensitivity to equity and comprehensive income., The JPY3.62bn net defined-benefit liability is a long-term obligation subject to discount-rate, asset-return, and actuarial assumptions..

Key concerns include Highest priority: restoration of gross margin and operating income after sales growth failed to translate into profit growth., Highest priority: reduction in receivable days, inventory days, and the 162-day annualized cash conversion cycle., High priority: verification that full-year attributable-profit progress is not interpreted as recurring, given the disposal gain., Moderate priority: refinancing discipline around the high short-term-debt mix despite ample current liquidity., Moderate priority: turnaround requirements in cosmetics materials, medical business, titanium dioxide/zinc products, and organic chemicals..

Investment Implications

Key takeaways include Sales momentum is positive, with Q1 revenue up 6.6% year on year and 26.3% progress against the full-year revenue forecast., Core earnings weakened: operating income fell 10.5%, gross margin declined about 240bp, and operating margin declined about 160bp., Electronic materials is the principal earnings engine, posting JPY0.58bn of segment profit and a 17.3% margin, while several legacy/materials businesses weakened., The 56.0% increase in attributable profit was largely non-recurring because JPY1.17bn of fixed-asset sale gains materially lifted earnings., Liquidity and solvency are strong, but cash-conversion efficiency is weak and should be treated as a central operating metric., The JPY160 per-share forecast dividend implies a 55.7% payout ratio on forecast EPS, supported by the balance sheet but dependent on recurring earnings delivery..

Metrics to watch include Gross margin and operating margin, particularly whether cost inflation and pricing normalize after Q1's 240bp gross-margin compression., Electronic-materials sales and segment margin, given its position as the core business., Titanium dioxide/zinc and organic-chemicals volumes, pricing, and segment-profit recovery., Cosmetics-materials and medical-business losses, including any additional impairment or restructuring charges., Annualized DSO, DIO, and cash conversion cycle versus the current 89 days, 131 days, and 162 days, respectively., Short-term debt share, cash/short-term debt coverage, and any change in refinancing structure., Recurrence of asset-sale gains and the gap between ordinary income and profit before tax..

Regarding relative positioning, The company combines a strong balance sheet and a diversified specialty-chemical/materials portfolio with a relatively low 7.9% Q1 operating margin versus the stated 8-15% good benchmark. Its minimal goodwill exposure and low leverage compare favorably with acquisition-heavy peers, while its unusually long working-capital cycle and uneven segment profitability are the principal relative constraints.